Ellison Institute of Technology

What Ellison Institute of Technology does

Ellison Institute of Technology (EIT) is a privately funded research institute, established in 2015 in Los Angeles by Larry Ellison (Oracle CTO) and Dr David Agus and reorganised around an Oxford, UK campus from October 2023. EIT operates as a multi-institute portfolio rather than a single product company, structured around eight research programs: the Generative Biology Institute (AI-driven genome writing and DNA sequence prediction), the Plant Biology Institute (climate-resilient crop science and the Wild Bioscience spinout), the AI & Robotics Institute (foundation models and autonomous labs), Materials & Devices for Life Sciences (nanopore diagnostics, 3D bioprinting), the Pathogen Program (including the EIT Pathogena cloud bioinformatics pipeline on Oracle infrastructure), Correlates of Immunity (vaccine development, including the £118m CoI-AI programme with the Oxford Vaccine Group), Lithium Air Batteries (clean energy and carbon sequestration), and the Africa Clinical Research Network, supported by an Economics Program and the Ellison Scholars fully funded scholarship at Oxford.

Underlying technology spans foundation models for biological sequence design, cloud-based genomic surveillance pipelines, autonomous robotic laboratories, nanopore-based point-of-care diagnostics, and bespoke 3D tissue bioprinters, with compute infrastructure provided via Oracle and access to the UK Dawn Supercomputer. EIT's go-to-market is hybrid: long-term strategic research alliances with universities (£130m Oxford alliance, £118m CoI-AI programme), technology licensing through Oxford University Innovation to spinouts (EIT Pathogena via GPAS; Constructive Biology; Genomics plc), venture investment in spinouts (leading Wild Bioscience's $60m Series A), and a small direct-to-patient oncology and preventative care clinic at the Oxford campus that integrates clinical care with research.

EIT is registered in England and Wales as Ellison Institute of Technology, Oxford Limited and is funded almost entirely by Larry Ellison's personal capital, with a £10 billion science investment plan announced in October 2025 supporting a planned 2 million sq ft Oxford campus (up to 7,000 staff by 2027) and construction costs exceeding £1 billion. Customer/user segments are diverse (academic researchers globally, scholarship students, oncology patients, spinout founders, government health agencies) but the funding base is a single source, making the entity a capital-intensive research platform rather than a commercial software or services business.

Name

Ellison Institute of Technology

Legal name

Ellison Institute of Technology, Oxford Limited

Website

https://eit.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Scientific Research and Technology Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Technical Universities with Computing, Data & AI Focus (EDAHAEAK)

akta.pro secondary industries

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Institutes of Technology (IoT / Technical Universities) (EDAHAEAC)

Keywords

• Scientific research services
• Generative biology research
• Genomic analysis software
• Oncology clinic services
• Graduate scholarship programs

Headquarters

HQ city

Littlemore

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Strategic Research Partnerships: EIT generates revenue through long-term strategic alliances with academic institutions, involving substantial investment in joint research programmes (£100m in Oxford partnership). These partnerships provide funding for research while creating pathways to commercialize scientific discoveries.
2. Technology Licensing: EIT licenses technologies developed through its research, such as EIT Pathogena, to commercial partners and healthcare organizations. Technology was developed by University of Oxford and licensed to GPAS by Oxford University Innovation.
3. Spinout Companies: EIT creates and supports spinout companies from its research, such as Constructive Biology (from Prof Jason Chin's work) and Wild Bioscience (in which EIT is a major investor), to commercialize innovations.
4. Healthcare Services: EIT operates an oncology and preventative care clinic at its Oxford campus, providing cutting-edge patient care while generating revenue to support research activities.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Ellison Institute of Technology (EIT) is a privately funded research institute that conducts scientific research and develops technologies across four domains: health and medical science, food security and sustainable agriculture, climate change and clean energy, and AI and robotics. It operates through a portfolio of specialized institutes and programs, licenses proprietary technologies such as the EIT Pathogena genomic analysis platform, runs an oncology and preventative care clinic, offers fully funded graduate and undergraduate scholarships at the University of Oxford, and creates and backs spinout companies commercializing its research.

Product overview

The Ellison Institute of Technology (EIT) is a research institute organized as a multi-institute portfolio, not a single unified product. It operates through distinct research institutes and programs that work in synergy: the Generative Biology Institute develops genome writing and AI-driven DNA prediction technologies; the Plant Biology Institute focuses on sustainable food production; the Pathogen Program (including EIT Pathogena) addresses infectious disease detection and prevention; the AI & Robotics Institute drives autonomous labs and AI-guided experiments; Materials & Devices for Life Sciences develops nanopore diagnostics and tissue engineering; Correlates of Immunity advances vaccine science; Lithium Air Batteries addresses clean energy; Africa Clinical Research Network accelerates trials; Economics Program applies economic analysis; Ellison Scholars Programme educates future innovators; and the EIT Oxford Clinic provides oncology and preventative care. EIT translates scientific discovery into real-world impact across four humane endeavors: Health/Medical Science/Generative Biology, Food Security/Sustainable Agriculture, Climate Change/Managing Atmospheric CO2, and AI/Robotics.

Differentiator

Problem solved

Functional benefit

Brands

• Generative Biology Institute (GBI): Building a global leading institute for engineering biology to develop technologies enabling genome writing and AI-driven prediction of DNA sequences.
• Plant Biology Institute
• AI & Robotics Institute
• Materials & Devices for Life Sciences Institute
• EIT Pathogena
• Ellison Scholars Programme

Products and services

• EIT Pathogena Cloud-based, automated bioinformatics pipeline enabling assembly, variant calling, species identification, drug susceptibility prediction, and outbreak cluster detection for mycobacterial pathogen genomes. Designed for researchers, academics, and public health organizations worldwide.
• EIT Oxford Clinic State-of-the-art oncology and preventative care clinic spanning 2,000 square metres with advanced on-site clinical imaging, designed to integrate research and clinical care for patients and healthcare providers.
• Ellison Scholars Programme Fully funded scholarship programme providing tuition, living expenses, and research support for exceptional undergraduate and graduate students to study at the University of Oxford while working on EIT projects. Open to exceptional students worldwide.
• Generative Biology Institute Research institute developing technologies enabling genome writing and AI-driven prediction of DNA sequences for specific biological functions, unlocking impact across health, agriculture, and clean energy. Hosts 30 group leaders and 300+ research staff.
• Plant Biology Institute Research institute developing impactful and commercially sustainable solutions for improving global food production and planetary health through pioneering plant science research leveraging AI and genetic technologies.
• AI & Robotics Institute Research institute advancing AI innovation grounded in human impact, combining foundation models with robotic hardware for autonomous labs, and producing AI-driven breakthroughs in science and healthcare.
• Materials & Devices for Life Sciences Institute Research institute developing nanopore diagnostic tools for point-of-care detection of proteins, peptides, and small molecules, and bespoke bioprinters and microfluidics for 3D tissue construction for drug screening and organ repair.

Quantifiable outcome

• Campus will house up to 7,000 researchers and staff
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Oxford Vaccine Group (University of Oxford)coreStrategic or Co-development Partner · 2 September 2025£118m research funding programme (CoI-AI) combining Oxford's expertise in human challenge studies, immune science and vaccine development with EIT's AI innovation technology. Programme studies immune responses to develop vaccines against serious infections including Streptococcus pneumoniae, Staphylococcus aureus, and E. coli.
• University of OxfordcoreStrategic or Co-development Partner · 3 December 2024Transformative strategic alliance with an investment of at least £130m from EIT, including £100m for joint research programmes and £30m for Centre for Doctoral Training in AI. The alliance brings together Oxford's world-leading researchers with EIT experts to tackle challenges across health, food security, climate, and AI. EIT has committed to recruiting approximately 20 undergraduate and postgraduate students annually through the Ellison Scholars programme.
• OraclecoreTechnology or IntegrationOracle provides computing infrastructure and cloud technology for EIT's operations, including the EIT Pathogena bioinformatics pipeline. Larry Ellison is CTO of Oracle. EIT benefits from Oracle's AI infrastructure capabilities including GPU infrastructure for AI datacentre development.
• Foster + PartnerscoreStrategic or Co-development PartnerWorld-renowned architectural firm led by Lord Norman Foster designing the EIT Oxford campus. Also leading the restoration of the historic Eagle and Child pub. The campus design creates a collaborative, nurturing environment to encourage research breakthroughs.
• Oxford University InnovationcoreTechnology or IntegrationTechnology transfer office of Oxford University that licensed EIT Pathogena technology to GPAS. OUI supports commercialization of Oxford research through managing licenses, clinical outcomes assessments, spinout companies, and Incubator.
• GPAS (Global Pathogen Analysis Service)coreTechnology or IntegrationGPAS Ltd was established during the pandemic to distribute the SARS-CoV-2 bioinformatics pipeline developed by Oxford's Modernising Medical Microbiology group. EIT Pathogena's technology was developed by University of Oxford and licensed to GPAS by Oxford University Innovation.
• Laing O'RourkeminorImplementation/ SI/ Consulting PartnerConstruction company building the new interdisciplinary research campus for EIT at Littlemore House within Oxford Science Park. Specialist Groundforce Shorco provides temporary hydraulic propping system for deep basement excavation.
• Groundforce ShorcominorImplementation/ SI/ Consulting PartnerSpecialist propping company providing complex temporary hydraulic propping system (MP250, MP375 and MP750 hydraulic props with capacities up to 750 tonnes) to support deep basement excavation for EIT campus construction.
• Tony Blair Institute for Global ChangeminorStrategic or Co-development PartnerEIT Faculty includes Tony Blair, Former UK PM and Executive Chairman of the TBI, as part of the distinguished group of world leaders, scientists and entrepreneurs. Dr Laura Gilbert leads AI for Government Programs within EIT's Applied Machine Learning team in close collaboration with TBI.
• ARC OxfordminorStrategic or Co-development PartnerARC Oxford leads the Campaign for Cowley Branch Line alongside EIT and The Oxford Science Park, advocating for re-opening of the rail line to transform Oxford's transport, housing and job opportunities.
• The Oxford Science ParkcoreStrategic or Co-development PartnerEIT's campus is located within The Oxford Science Park. Partnership includes joint advocacy for Cowley Branch Line reopening and collaboration on science and innovation initiatives.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Altos Labs: Also backed by Larry Ellison, Altos Labs is a private biological research company focused on cellular rejuvenation and longevity. Comparable as a privately-funded, Ellison-backed science institute pursuing ambitious life-science research with world-class academic talent.
• Wellcome Trust / Wellcome Sanger Institute: A large UK-based charitable foundation supporting biomedical and genomics research, including the Wellcome Sanger Institute. Comparable in scale, mission, and focus on genomics, infectious disease, and population health, with similar Oxford-UK ecosystem overlap.
• Chan Zuckerberg Initiative (CZI): A private philanthropic organization founded by a tech billionaire (Mark Zuckerberg) that funds biomedical research, AI, and education. Directly comparable in structure as a tech-wealth-funded research and science translation platform.
• Howard Hughes Medical Institute (HHMI): A large US-based private biomedical research organization supporting investigator-led science. Comparable in model: private, philanthropy-funded, supports world-class investigators across multiple research institutions and program areas.
• The Francis Crick Institute: A major UK biomedical discovery research institute in London. Comparable as a large UK research institute operating across multiple biomedical disciplines with a focus on fundamental discovery and translation.
• MRC Laboratory of Molecular Biology (MRC-LMB): A premier UK molecular biology research institute where EIT's Generative Biology Director (Prof Jason Chin) was previously a Programme Leader. Comparable in cutting-edge molecular biology research and is a key source of talent for EIT.
• Allen Institute: A private research organization founded by Paul Allen that conducts large-scale research in neuroscience, cell science, and AI. Comparable as a private tech-philanthropy-funded research institute pursuing frontier science with big-team research models.

Emerging players

• Arc Institute: A private research institute in California focused on complex human disease, combining AI and experimental biology. Comparable as an emerging private research institute pursuing AI-driven biology, founded with significant tech-philanthropy funding.

Broad incumbents

• Broad Institute of MIT and Harvard: A leading US biomedical and genomic research institute affiliated with MIT and Harvard. Comparable in genomic medicine, large-scale data science, and translational research mission, though it is university-affiliated rather than private.

Others

• Schmidt Futures: A philanthropic initiative founded by Eric and Wendy Schmidt supporting science, talent, and AI. Comparable as a tech-philanthropy-backed organization investing in research talent and emerging science, with overlap via EIT's education director previously working on Rise scholarship.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EITOxford
• Facebookfacebook.com/EITOxford
• LinkedInlinkedin.com/company/eitoxford
• Instagraminstagram.com/eitoxford

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ellison Institute of Technology